Luc F. Van Gaal

Q: What Schools Are Affiliated With Luc F. Van Gaal

Luc F. Van Gaal is affiliated with the following schools: University of Liverpool, University of Antwerp

Luc F. Van Gaal's AcademicInfluence.com Rankings

Luc F. Van Gaal

Philosophy

#9034

World Rank

#12527

Historical Rank

Logic

#6036

World Rank

#7513

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Luc F. Van Gaal's Degrees

PhD Medicine University of Amsterdam
Doctorate Medicine University of Amsterdam

Why Is Luc F. Van Gaal Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Luc F. Van Gaal's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. (2010) (839)
Once-Weekly Semaglutide in Adults with Overweight or Obesity. (2021) (630)
Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 Diabetes (2005) (549)
Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide (2011) (549)
Human leptin: from an adipocyte hormone to an endocrine mediator. (2000) (479)
TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease (2014) (468)
Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis (2016) (426)
Body surface area in normal-weight, overweight, and obese adults. A comparison study. (2006) (387)
The beneficial effects of modest weight loss on cardiovascular risk factors. (1997) (313)
Overweight, obesity, and blood pressure: the effects of modest weight reduction. (2000) (308)
The Effect of Exercise on Visceral Adipose Tissue in Overweight Adults: A Systematic Review and Meta-Analysis (2013) (285)
Sleep-disordered breathing in overweight and obese children and adolescents: prevalence, characteristics and the role of fat distribution (2006) (245)
PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis. (2015) (226)
Association of Adipose Tissue Inflammation With Histologic Severity of Nonalcoholic Fatty Liver Disease. (2015) (223)
The prevalence, anatomical correlates and treatment of sleep-disordered breathing in obese children and adolescents. (2008) (193)
Type 1 diabetes and autoimmune polyglandular syndrome: a clinical review. (2009) (175)
Advances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From a Diabetes Care Editors’ Expert Forum (2015) (167)
Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes. (2014) (162)
Weight Management in Type 2 Diabetes: Current and Emerging Approaches to Treatment (2015) (160)
Progress and challenges in anti-obesity pharmacotherapy. (2017) (159)
Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes. (2018) (159)
Variants in the FTO gene are associated with common obesity in the Belgian population. (2008) (157)
Efficacy and Safety of Rimonabant for Improvement of Multiple Cardiometabolic Risk Factors in Overweight/Obese Patients (2008) (156)
Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study. (2008) (147)
Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial. (2014) (145)
Management of familial hypercholesterolemia in children and young adults: consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization. (2011) (144)
Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults (2013) (142)
Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial (2012) (140)
Sleep-disordered breathing and the metabolic syndrome in overweight and obese children and adolescents. (2007) (138)
Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. (2007) (135)
Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study (1998) (135)
Prothrombotic factors in histologically proven nonalcoholic fatty liver disease and nonalcoholic steatohepatitis (2014) (134)
Reference values for sleep‐related respiratory variables in asymptomatic European children and adolescents (2007) (130)
Transcriptional Activation of Apolipoprotein CIII Expression by Glucose May Contribute to Diabetic Dyslipidemia (2011) (128)
Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges? (2014) (125)
Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipids (2013) (123)
Autoimmune gastritis in type 1 diabetes: a clinically oriented review. (2008) (115)
Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjects. (2009) (114)
Effect of Long-Term Whole Body Vibration Training on Visceral Adipose Tissue: A Preliminary Report (2010) (111)
Prevalence of Loss-of-Function FTO Mutations in Lean and Obese Individuals (2009) (110)
High frequency of persisting or increasing islet-specific autoantibody levels after diagnosis of type 1 diabetes presenting before 40 years of age. The Belgian Diabetes Registry. (2000) (109)
Noninvasive Detection of Nonalcoholic Steatohepatitis Using Clinical Markers and Circulating Levels of Lipids and Metabolites. (2016) (106)
Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease. (2012) (105)
Addition of rosiglitazone to metformin is most effective in obese, insulin‐resistant patients with type 2 diabetes (2003) (104)
Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel (2005) (103)
Flow mediated dilatation and cardiac function in type 1 diabetes mellitus. (2006) (101)
Heterozygous Mutations Causing Partial Prohormone Convertase 1 Deficiency Contribute to Human Obesity (2012) (99)
Loss-of-function mutations in SIM1 contribute to obesity and Prader-Willi-like features. (2013) (99)
Leptin receptor gene polymorphisms are associated with insulin in obese women with impaired glucose tolerance. (2001) (98)
Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity (2019) (97)
Leptin levels in type 2 diabetes: associations with measures of insulin resistance and insulin secretion. (2003) (97)
C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patients. (2011) (95)
Mutation analysis of the MEN1 gene in Belgian patients with multiple endocrine neoplasia type 1 and related diseases (1999) (92)
Safety and Efficacy of Once-Weekly Exenatide Compared With Insulin Glargine Titrated to Target in Patients With Type 2 Diabetes Over 84 Weeks (2012) (88)
Belgian consensus on metabolic problems associated with atypical antipsychotics (2005) (86)
Leisure-time activity is an important determinant of long-term weight maintenance after weight loss in the Sibutramine Trial on Obesity Reduction and Maintenance (STORM trial). (2003) (84)
Impact of overweight on chronic microvascular complications in type 1 diabetic patients. (2005) (83)
Autoimmune gastropathy in type 1 diabetic patients with parietal cell antibodies: histological and clinical findings. (2003) (82)
Noninvasive assessment of nonalcoholic fatty liver disease in obese or overweight patients. (2012) (80)
Interspecies NASH disease activity whole-genome profiling identifies a fibrogenic role of PPARα-regulated dermatopontin. (2017) (80)
Contribution of Antibodies Against IA-2β and Zinc Transporter 8 to Classification of Diabetes Diagnosed Under 40 Years of Age (2011) (79)
Transcriptional network analysis implicates altered hepatic immune function in NASH development and resolution (2019) (78)
Association of the BDNF Val66Met variation with obesity in women. (2008) (78)
Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results (2008) (75)
Sleep-disordered breathing, obesity, and airway inflammation in children and adolescents. (2008) (74)
Impact of diabetes mellitus on the relationships between iron‐, inflammatory‐ and oxidative stress status (2006) (74)
Rimonabant as an adjunct therapy in overweight/obese patients with type 2 diabetes. (2007) (73)
Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients (2002) (72)
Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial. (2009) (71)
Bile Acid Alterations Are Associated With Insulin Resistance, but Not With NASH, in Obese Subjects (2017) (71)
A rapid and simple method for measuring the susceptibility of low-density-lipoprotein and very-low-density-lipoprotein to copper-catalyzed oxidation. (1994) (71)
Daily intake of bisphenol A and triclosan and their association with anthropometric data, thyroid hormones and weight loss in overweight and obese individuals. (2015) (67)
The in vitro oxidizability of lipoprotein particles in obese and non-obese subjects. (1998) (67)
Visceral fat is a determinant of PAI-1 activity in diabetic and non-diabetic overweight and obese women. (2001) (65)
Intensive Insulin Therapy in the Intensive Care Unit (2006) (64)
Phthalate metabolites in obese individuals undergoing weight loss: Urinary levels and estimation of the phthalates daily intake. (2013) (63)
Uric Acid as a Risk Factor for Cardiovascular Disease and Mortality in Overweight/Obese Individuals (2013) (62)
Considerable exposure to the endocrine disrupting chemicals phthalates and bisphenol-A in intensive care unit (ICU) patients. (2015) (61)
Exposure to Persistent Organic Pollutants: Relationship With Abnormal Glucose Metabolism and Visceral Adiposity (2014) (60)
Noncirrhotic human nonalcoholic fatty liver disease induces portal hypertension in relation to the histological degree of steatosis (2010) (60)
Visceral fat as a determinant of fibrinolysis and hemostasis. (2005) (60)
Human obesity: from lipid abnormalities to lipid oxidation. (1995) (59)
Pro-Inflammatory Cytokines but Not Endotoxin-Related Parameters Associate with Disease Severity in Patients with NAFLD (2016) (59)
X‐PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced‐energy diet. Early response to treatment predicts weight maintenance (2005) (58)
Sleep-disordered breathing and uric acid in overweight and obese children and adolescents. (2007) (57)
Soluble transferrin receptor level: a new marker of iron deficiency anemia, a common manifestation of gastric autoimmunity in type 1 diabetes. (2000) (55)
Usefulness of fluoxetine in obese non-insulin-dependent diabetics: a multicenter study. (1996) (54)
Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control? (2008) (54)
Leptin levels, leptin receptor gene polymorphisms, and energy metabolism in women. (2002) (54)
Peripheral and Hepatic Vein Cytokine Levels in Correlation with Non-Alcoholic Fatty Liver Disease (NAFLD)-Related Metabolic, Histological, and Haemodynamic Features (2015) (53)
Initiating oral glucose-lowering therapy with metformin in type 2 diabetic patients: an evidence-based strategy to reduce the burden of late-developing diabetes complications. (2004) (51)
Delayed gastric emptying and gastric autoimmunity in type 1 diabetes. (2002) (49)
Screening for therapeutic trials and treatment indication in clinical practice: MACK‐3, a new blood test for the diagnosis of fibrotic NASH (2018) (47)
Can red yeast rice and olive extract improve lipid profile and cardiovascular risk in metabolic syndrome?: a double blind, placebo controlled randomized trial (2015) (47)
The role of the leptin-melanocortin signalling pathway in the control of food intake. (2009) (46)
Sibutramine and fat distribution: is there a role for pharmacotherapy in abdominal/visceral fat reduction? (1998) (46)
A Review of Current Evidence with Continuous Glucose Monitoring in Patients with Diabetes (2008) (45)
LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial (2016) (45)
Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing’s disease: results from an open-ended, open-label extension trial (2014) (45)
High prevalence of manifestations of gastric autoimmunity in parietal cell antibody-positive type 1 (insulin-dependent) diabetic patients. The Belgian Diabetes Registry. (1999) (44)
Effects of pravastatin on lipid levels, in vitro oxidizability of non-HDL lipoproteins and microalbuminuria in IDDM patients. (1995) (43)
Gastric parietal cell antibodies are associated with glutamic acid decarboxylase‐65 antibodies and the HLA DQA1*0501‐DQB1*0301 haplotype in Type 1 diabetes mellitus (2000) (43)
Association between polymorphisms of the Nesfatin gene, NUCB2, and obesity in men. (2011) (42)
Dynamics of organohalogenated contaminants in human serum from obese individuals during one year of weight loss treatment. (2013) (42)
Current concepts in gastric motility in diabetes mellitus. (2006) (42)
Muscle fat content is strongly associated with NASH: a longitudinal study in patients with morbid obesity. (2021) (42)
Long term magnesium supplementation influences favourably the natural evolution of neuropathy in Mg-depleted type 1 diabetic patients (T1dm). (2004) (41)
Miglitol combined with metformin improves glycaemic control in type 2 diabetes (2001) (41)
Association study of MC4R with complex obesity and replication of the rs17782313 association signal. (2011) (41)
Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat Dose-Ranging Study Group. (1998) (40)
Intensive insulin therapy in the intensive care unit: assessment by continuous glucose monitoring (2005) (40)
Phenotypic expression and frequency of familial defective apolipoprotein B-100 in Belgian hypercholesterolemics. (1994) (40)
Inverse relationship between plasminogen activator inhibitor-I activity and adiponectin in overweight and obese women. Interrelationship with visceral adipose tissue, insulin resistance, HDL-chol and inflammation. (2005) (40)
Expression of Obesity Markers and Persistent Organic Pollutants Levels in Adipose Tissue of Obese Patients: Reinforcing the Obesogen Hypothesis? (2014) (39)
Apolipoprotein concentrations in obese subjects with upper and lower body fat mass distribution. (1989) (39)
Urinary phthalate metabolites are associated with insulin resistance in obese subjects. (2015) (38)
Elevated plasminogen activator inhibitor levels in cyclosporin-treated renal allograft recipients. (1996) (38)
Insulin Resistance and Environmental Pollutants: Experimental Evidence and Future Perspectives (2013) (37)
Sarcopenia in patients with non‐alcoholic fatty liver disease: is it a clinically significant entity? (2018) (36)
Pharmacological Approaches in the Treatment and Maintenance of Weight Loss (2016) (35)
Upper body adiposity and the risk for atherosclerosis. (1989) (35)
Hemoperfusion-hemodialysis ineffective for paraquat removal in life-threatening poisoning? (1985) (35)
SULF2 strongly prediposes to fasting and postprandial triglycerides in patients with obesity and type 2 diabetes mellitus (2014) (34)
Resting metabolic rate is an important predictor of serum adiponectin concentrations: potential implications for obesity-related disorders. (2005) (33)
Glucose control and use of continuous glucose monitoring in the intensive care unit: a critical review. (2008) (33)
Helicobacter pylori, parietal cell antibodies and autoimmune gastropathy in type 1 diabetes mellitus (2002) (33)
Anti-obesity drugs: what does sibutramine offer? An analysis of its potential contribution to obesity treatment. (2009) (33)
Twenty-Year Progression Rate to Clinical Onset According to Autoantibody Profile, Age, and HLA-DQ Genotype in a Registry-Based Group of Children and Adults With a First-Degree Relative With Type 1 Diabetes (2017) (33)
Blood pressure changes associated with sibutramine and weight management – an analysis from the 6‐week lead‐in period of the sibutramine cardiovascular outcomes trial (SCOUT) * (2009) (32)
Gender differences in leptin levels and physiology: a role for leptin in human reproduction. (1999) (31)
Identification of Three Novel Genetic Variants in the Melanocortin‐3 Receptor of Obese Children (2011) (31)
Hepatocyte-specific loss of GPS2 in mice reduces non-alcoholic steatohepatitis via activation of PPARα (2019) (31)
Coenzyme Q as an antiadipogenic factor. (2011) (30)
Blood viscosity in human obesity: relation to glucose tolerance and insulin status. (1989) (30)
Autoimmune hepatitis, autoimmune gastritis, and gastric carcinoid in a type 1 diabetic patient: a case report. (2000) (29)
Association of Hypoglycemic Treatment Regimens With Cardiovascular Outcomes in Overweight and Obese Subjects With Type 2 Diabetes (2013) (28)
The role of nocturnal pulse oximetry in the screening for obstructive sleep apnea in obese children and adolescents. (2015) (28)
[Conference report: Belgian consensus on metabolic problems associated with atypical antipsychotics]. (2005) (28)
Early endothelial dysfunction in young type 1 diabetics. (2009) (28)
Minimally-invasive and non-invasive continuous glucose monitoring systems: indications, advantages, limitations and clinical aspects. (2008) (28)
Pivotal Role for the Visceral Fat Compartment in the Release of Persistent Organic Pollutants During Weight Loss. (2015) (27)
Plasma BCAA changes in Patients with NAFLD are Sex Dependent. (2020) (26)
Predicting type 2 diabetes mellitus: a comparison between the FINDRISC score and the metabolic syndrome (2018) (26)
Neuroendocrine tumor markers and enterochromaffin-like cell hyper/dysplasia in type 1 diabetes. (2004) (26)
Liraglutide 3.0 mg for weight management: weight-loss dependent and independent effects (2017) (25)
Hemostasis and fibrinolysis in non-diabetic overweight and obese men and women. Is there still a role for leptin? (2006) (25)
The age at diagnosis of type 1 diabetes continues to decrease in Belgian boys but not in girls: a 15‐year survey (2007) (25)
Echocardiographic Evidence for Valvular Toxicity of Benfluorex: A Double-Blind Randomised Trial in Patients with Type 2 Diabetes Mellitus (2012) (25)
Sleep duration and metabolic dysregulation in overweight children and adolescents (2007) (25)
Factors determining energy expenditure during very-low-calorie diets. (1992) (24)
CNV analysis and mutation screening indicate an important role for the NPY4R gene in human obesity (2016) (24)
Impact of Vitamin E supplementation on lipoprotein peroxidation and composition in Type 1 diabetic patients treated with Atorvastatin. (2004) (24)
Screening for type 2 diabetes mellitus in overweight and obese subjects made easy by the FINDRISC score. (2016) (23)
Copy number variation (CNV) analysis and mutation analysis of the 6q14.1-6q16.3 genes SIM1 and MRAP2 in Prader Willi like patients. (2016) (23)
Rationale and options for combination therapy in the treatment of Type 2 diabetes (2003) (23)
Fluoxetine therapy in obese diabetic and glucose intolerant patients. (1992) (23)
Metabolic syndrome in youth: a cross‐sectional school‐based survey (2007) (23)
Dose-response of simvastatin in primary hypercholesterolemia. (1994) (22)
Do E‐cigarettes induce weight changes and increase cardiometabolic risk? A signal for the future (2017) (22)
Efficacy and safety of the glucagon-like peptide-1 receptor agonist lixisenatide versus the dipeptidyl peptidase-4 inhibitor sitagliptin in young (<50 years) obese patients with type 2 diabetes mellitus☆ (2014) (22)
Associations of leptin with body fat distribution and metabolic parameters in non-insulin-dependent diabetic patients: no effect of apolipoprotein E polymorphism. (2000) (22)
Are all glitazones the same? (2002) (21)
Assessment of body composition by skinfold anthropometry and bioelectrical impedance technique: a comparative study. (1994) (21)
Sleep-disordered breathing, systemic adipokine secretion, and metabolic dysregulation in overweight and obese children and adolescents. (2017) (21)
Magnesium and obesity: influence of gender, glucose tolerance, and body fat distribution on circulating magnesium concentrations. (1992) (21)
Identification of mutations in the NUCB2/nesfatin gene in children with severe obesity. (2012) (20)
Anthropometric and calorimetric evidence for the protein sparing effects of a new protein supplemented low calorie preparation. (1985) (20)
Overweight in adolescents: differences per type of education. Does one size fit all? (2008) (20)
New International Diabetes Federation (IDF) and National Cholesterol Education Program Adult Treatment panel III (NCEP‐ATPIII) criteria and the involvement of hemostasis and fibrinolysis in the metabolic syndrome (2006) (20)
Impact of waist circumference difference on health-care cost among overweight and obese subjects: the PROCEED cohort. (2010) (20)
Circulating PCSK9 levels are not associated with the severity of hepatic steatosis and NASH in a high-risk population. (2018) (20)
Weight and blood pressure response to weight management and sibutramine in diabetic and non‐diabetic high‐risk patients: an analysis from the 6‐week lead‐in period of the sibutramine cardiovascular outcomes (SCOUT) trial (2010) (20)
The Effect of Lifestyle Interventions on Excess Ectopic Fat Deposition Measured by Noninvasive Techniques in Overweight and Obese Adults: A Systematic Review and Meta-Analysis. (2016) (20)
Identification and Functional Characterization of Novel Mutations in the Melanocortin-4 Receptor (2010) (20)
Repaglinide improves blood glucose control in sulphonylurea-naive type 2 diabetes. (2001) (19)
A red yeast rice-olive extract supplement reduces biomarkers of oxidative stress, OxLDL and Lp-PLA2, in subjects with metabolic syndrome: a randomised, double-blind, placebo-controlled trial (2017) (19)
Sleep-disordered breathing and pulmonary function in obese children and adolescents. (2014) (19)
Is visceral adipose tissue a determinant of von Willebrand factor in overweight and obese premenopausal women? (2006) (19)
A comparison of two insulin infusion protocols in the medical intensive care unit by continuous glucose monitoring (2016) (19)
Plasma adiponectin level is inversely correlated with albuminuria in overweight and obese nondiabetic individuals. (2013) (19)
Postprandial glucose monitoring in type 1 diabetes mellitus: use of a continuous subcutaneous monitoring device (2004) (19)
LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial (2016) (18)
The safety of obesity drugs – correspondence (2007) (17)
New approaches for the management of patients with multiple cardiometabolic risk factors. (2006) (17)
Importance of glucagon as a determinant of resting metabolic rate and glucose-induced thermogenesis in obese women. (1991) (17)
Sleep-disordered breathing and systemic inflammation in overweight children and adolescents. (2008) (16)
Sex hormones, body fat distribution, resting metabolic rate and glucose-induced thermogenesis in premenopausal obese women. (1994) (16)
A case of malnutrition after biliopancreatic diversion for morbid obesity. (1993) (16)
Sleep disordered breathing and autonomic function in overweight and obese children and adolescents (2016) (16)
Monogenic and complex forms of obesity: insights from genetics reveal the leptin-melanocortin signaling pathway as a common player. (2012) (16)
Weight reduction with a high protein, low carbohydrate, calorie-restricted diet: effects on blood pressure, glucose and insulin levels. (1989) (16)
Endocrine-disrupting polychlorinated biphenyls in metabolically healthy and unhealthy obese subjects before and after weight loss: difference at the start but not at the finish. (2016) (16)
Effects of dexfenfluramine on resting metabolic rate and thermogenesis in premenopausal obese women during therapeutic weight reduction. (1995) (16)
Prevalence of rare MC3R variants in obese cases and lean controls (2013) (15)
The effect of diet or exercise on ectopic adiposity in children and adolescents with obesity: a systematic review and meta‐analysis (2017) (15)
Time Course of Oxidative Stress Status in the Postprandial and Postabsorptive States in Type 1 Diabetes Mellitus: Relationship to Glucose and Lipid Changes (2005) (15)
Short and long term effects of a very low calorie diet on resting metabolic rate and body composition. (1989) (15)
Misdiagnosis of Graves’ hyperthyroidism due to therapeutic biotin intervention (2017) (15)
Long-term health considerations in schizophrenia: metabolic effects and the role of abdominal adiposity. (2006) (15)
Relation between disease phenotype and HLA-DQ genotype in diabetic patients diagnosed in early adulthood. (2002) (15)
Modern, new pharmacotherapy for obesity. A gastrointestinal approach. (2004) (14)
Association Study and Mutation Analysis of Adiponectin Shows Association of Variants in APM1 with Complex Obesity in Women (2009) (14)
Decreased diet-induced thermogenesis in gluteal-femoral obesity. (1989) (14)
Replication of the SH2B1 rs7498665 Association with Obesity in a Belgian Study Population (2011) (14)
Dynamics of persistent organic pollutants in obese adolescents during weight loss. (2018) (14)
NASH-related increases in plasma bile acid levels depend on insulin resistance (2020) (14)
Glucose Intolerance and the Amount of Visceral Adipose Tissue Contribute to an Increase in Circulating Triglyceride Concentrations in Caucasian Obese Females (2012) (13)
Health risks of lipodystrophy and abdominal fat accumulation: therapeutic possibilities with leptin and human growth hormone. (2003) (12)
Obesity in Europe – does anybody care? (2013) (12)
Effects of acarbose on carbohydrate metabolism, electrolytes, minerals and vitamins in fairly well-controlled non-insulin-dependent diabetes mellitus. (1991) (12)
Role of hepatic arterial embolisation in the treatment for metastatic insulinoma. Report of two cases and review of the literature. (1997) (12)
Decreased hepatic insulin extraction in upper body obesity: relationship to unbound androgens and sex hormone binding globulin. (1991) (12)
Accurate non‐invasive diagnosis and staging of non‐alcoholic fatty liver disease using the urinary steroid metabolome (2020) (12)
Low-density lipoprotein receptor gene mutation analysis and clinical correlation in Belgian hypercholesterolaemics. (2001) (11)
GLP-1 receptor agonists for type 2 diabetes. (2009) (11)
Screening for genetic variants in BDNF that contribute to childhood obesity (2014) (11)
A Preliminary Link between Hydroxylated Metabolites of Polychlorinated Biphenyls and Free Thyroxin in Humans (2016) (11)
Genetic association between WNT10B polymorphisms and obesity in a Belgian case-control population is restricted to males. (2012) (11)
Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program (2019) (11)
Clinical Predictors of Residual Sleep Apnea after Weight Loss Therapy in Obese Adolescents (2018) (11)
Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analogue, liraglutide (2012) (10)
Drugs Affecting Body Weight, Body Fat Distribution, and Metabolic Function—Mechanisms and Possible Therapeutic or Preventive Measures: an Update (2021) (10)
The metabolic syndrome and the liver. (2008) (10)
Identification of prediabetes in first‐degree relatives at intermediate risk of type I diabetes (2007) (10)
Common melanocortin-3 receptor variants are not associated with obesity, although rs3746619 does influence weight in obese individuals (2010) (10)
Belgian expert opinion: how to reduce the residual risk in atherogenic dyslipidaemic patients: place of fibrates (2008) (10)
Evaluation of magnesium before and after jejuno-ileal versus gastric bypass surgery for morbid obesity. (1987) (9)
Sleep-Disordered Breathing and Proteinuria in Overweight and Obese Children and Adolescents (2008) (9)
Relation between weight loss and causes of death in patients with cardiovascular disease: finding from the SCOUT trial (2017) (9)
Hypertension in obese and non-obese non-insulin dependent diabetics a matter of regional adiposity? (1988) (8)
Plasma zinc levels in diabetes mellitus: relation to plasma albumin and amino acids. (1986) (8)
Genetic and structural variation in the SH2B1 gene in the Belgian population. (2015) (8)
Opposite effects of insulin-like molecules and leptin in coronary heart disease of type 2 diabetes Preliminary data. (2006) (8)
Evaluation of a Role for NPY and NPY2R in the Pathogenesis of Obesity by Mutation and Copy Number Variation Analysis in Obese Children and Adolescents (2018) (8)
Common genetic variation in sFRP5 is associated with fat distribution in men (2014) (8)
Adiponectin levels do not predict clinical onset of type 1 diabetes in antibody-positive relatives (2007) (8)
Three-year efficacy and safety of exenatide once weekly: A pooled analysis of three trials. (2017) (8)
Relationship of body mass index with efficacy of exenatide twice daily added to insulin glargine in patients with type 2 diabetes (2016) (8)
Prolyl carboxypeptidase activity in the circulation and its correlation with body weight and adipose tissue in lean and obese subjects (2018) (7)
Incidence and predisposing factors for the development of disturbed glucose metabolism and DIabetes mellitus AFter Intensive Care admission: the DIAFIC study (2015) (7)
Effect of a long term very low calorie diet on glucose/insulin metabolism in obesity. Influence of fat distribution on hepatic insulin extraction. (1989) (7)
Magnesium and obesity: effects of treatment on magnesium and other parameters. (1987) (7)
Prolonged flare-up of testosterone after administration of a gonadotrophin agonist to a sex offender: an under-recognised risk? (2015) (7)
Impact of obesity on resting metabolic rate and glucose-induced thermogenesis in non-insulin dependent diabetes mellitus. (1992) (7)
Lipid and lipoprotein changes after long-term weight reduction: the influence of gender and body fat distribution. (1995) (7)
Bariatric surgery to treat type 2 diabetes: what is the recent evidence? (2012) (7)
PAI‐1 activity, but not fibrinogen or von Willebrand factor, is inversely related to LDL particle size in type 2 diabetes (2008) (7)
Fainting and hemolysis during blood sampling in youngsters: prevalence study. (2008) (6)
Blood rheology during an intensified conventional insulin treatment (ICIT) in insulin-dependent diabetes. (1989) (6)
Coronary artery calcifications and diastolic dysfunction versus visceral fat area in type 1 diabetes: VISCERA study. (2017) (6)
Abnormal longitudinal peak systolic strain in asymptomatic patients with type I diabetes mellitus (2019) (6)
Diabetic keto-acidosis as a presentation of cystic fibrosis-related diabetes: a case report. (2011) (6)
Changes in vitamin E status during obesity treatment. (1987) (6)
Operations for failed vertical banded gastroplasty. (1994) (6)
Efficacy and safety of high-dose GLP-1, GLP-1/GIP and GLP-1/glucagon receptor agonists in type 2 diabetes. (2022) (6)
Changes in body weight and pulse: outcome events in overweight and obese subjects with cardiovascular disease in the SCOUT trial (2014) (6)
Patient engagement impacts glycemic management with vildagliptin and vildagliptin/metformin (single pill) regimens in type 2 diabetes mellitus (the GLORIOUS study). (2016) (6)
Association study of PNPLA2 gene with histological parameters of NAFLD in an obese population. (2016) (5)
A targeted multi-omics approach reveals paraoxonase-1 as a determinant of obesity-associated fatty liver disease (2021) (5)
NAFLD in type 1 diabetes: overrated or underappreciated? (2021) (5)
[Clinical study of the month. Accord-lipid and accord-eye: towards a new positioning of fenofibrate in the management of type 2 diabetes]. (2010) (5)
Randomized Evaluation of Glycemic Control in the Medical Intensive Care Unit Using Real-Time Continuous Glucose Monitoring (REGIMEN Trial). (2015) (5)
Response to Comment on Home et al. Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges? Diabetes Care 2014;37:1499–1508 (2014) (5)
Cardiometabolic importance of 1-h plasma glucose in obese subjects (2019) (5)
Hyperkalemia in Diabetic Ketoacidosis (1981) (4)
Adenotonsillectomy as first-line treatment for sleep-disordered breathing in obese children. (2008) (4)
[Cardiometabolic effects of rimonabant in obese/overweight subjects with dyslipidaemia or type 2 diabetes]. (2007) (4)
The Cushing Reflex: Oliguria as a Reflection of an Elevated Intracranial Pressure (2017) (4)
Association of 1-deoxy-sphingolipids with steatosis but not steatohepatitis nor fibrosis in non-alcoholic fatty liver disease (2020) (4)
Copy number variant analysis and expression profiling of the olfactory receptor-rich 11q11 region in obesity predisposition (2020) (4)
[Sitagliptine (Januvia): incretin enhancer potentiating insulin secretion for the treatment of type 2 diabetes]. (2008) (4)
Posttranscriptional Regulation of the Human LDL Receptor by the U2-Spliceosome (2021) (3)
Repeated measurements of bioelectrical impedance. (1994) (3)
Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed‐ratio combination: a post hoc analysis of the LixiLan‐O and LixiLan‐L trials (2019) (3)
Therapeutic approaches for non-alcoholic steatohepatitis (2021) (3)
Effectiveness and Tolerability of Vildagliptin and the Single Pill Combination of Vildagliptin and Metformin in “Real-World” Management of Type 2 Diabetes Mellitus: The G-FORCE Study (2019) (3)
Screening for rare variants in the PNPLA3 gene in obese liver biopsy patients. (2016) (3)
Investigation of common and rare genetic variation in the BAMBI genomic region in light of human obesity (2016) (3)
Effects of micronized fenofibrate and vitamin E on in vitro oxidation of lipoproteins in patients with type 1 diabetes mellitus. (2005) (3)
Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study (2021) (3)
[The cost of type 2 diabetes: summary of the Cost of Diabetes in Europe-Type II study (CODE-2) and analysis of the situation in Belgium]. (2005) (3)
[Liraglutide (Victoza): human glucagon-like peptide-1 used in once daily injection for the treatment of type 2 diabetes]. (2010) (3)
Health-related costs in a sample of premenopausal non-diabetic overweight or obese females in Antwerp region: a cost-of-illness analysis (2018) (3)
Identification and functional characterization of a missense mutation in resistin in two patients with severe obesity and insulin resistance. (2011) (3)
Author Correction: Transcriptional network analysis implicates altered hepatic immune function in NASH development and resolution (2019) (3)
Effects of smoking on lipid parameters during therapeutic weight loss. (1986) (3)
Hypothyroidism and prolactin. (1981) (2)
Obesity, health issues, and cardiovascular disease. (2005) (2)
Intronic mutations at splice junctions in the low-density lipoprotein receptor gene. (1999) (2)
[Effects of the relative enrichment of polyunsaturated fatty acids in insulin-dependent diabetic patients]. (1986) (2)
Tackling obesity during the COVID‐19 pandemic (2020) (2)
Evolution of Serum α‐Tocopherol in the Postprandial and Postabsorptive Phases in Type 1 Diabetes Mellitus (2004) (2)
No conclusive evidence for association of polymorphisms in the adiponectin receptor 1 gene, AdipoR1, with common obesity (2013) (2)
Nucleotide variation of sFRP5 gene is not associated with obesity in children and adolescents (2016) (2)
[Linagliptin (Trajenta): a selective DPP-4 inhibitor with limited renal elimination]. (2012) (2)
[Sugar: results of a Belgian observational study on the use of sitagliptin in patients with type 2 diabetes]. (2010) (2)
[Medication of the month... Exenatide (Byetta) incretinomimetic in the treatment of type 2 diabetes after failure and as add-on therapy to oral agents]. (2008) (2)
Vaping and Cardiovascular Health: the Case for Health Policy Action (2019) (2)
22nd European Congress on Obesity (ECO2015), Prague, Czech Republic, May 6-9, 2015: Abstracts (2015) (2)
[Endocannabinoid system in the brain...and elsewhere]. (2008) (2)
[Improved glucose control and weight loss with exenatide in patients with type 2 diabetes: results of a retrospective observational multicentre Belgian study]. (2009) (2)
Features of oral glucose tolerance tests in patients after Roux‐en‐Y gastric bypass with and without hypoglycaemia symptoms in daily life: It's all about speed (2020) (2)
Vitamin E status in gold-thioglucose-treated obese mice: the influence of weight loss. (1985) (2)
Reducing cardiometabolic risk through selective antagonism of CB1 receptors. (2007) (1)
Sleep duration and insulin resistance in obese children: when variables are sleeping too close together. (2007) (1)
Inverse relationship between plasminogen activator inhibitor-1 activity and adiponectin in overweight and obese women (2005) (1)
Assessing the impact of complications on the costs of Type II diabetes. (2002) (1)
Can Bariatric Surgery be Considered Standard Therapy to Treat Type 2 Diabetes? (2013) (1)
Efficacy and safety of exenatide once weekly: an overview of the DURATION trials (2012) (1)
European Obesity Summit (EOS) – Joint Congress of EASO and IFSO-EC, Gothenburg, Sweden, June 1 – 4, 2016: Abstracts (2016) (1)
Cushing's syndrome, due to ectopic ACTH-secretion, successfully treated with aminoglutethimide, radiotherapy and chemotherapy. (1981) (1)
European Obesity Summit (EOS) – Joint Congress of EASO and IFSO-EC, Gothenburg, Sweden, June 1 – 4, 2016: Abstracts (2016) (1)
[Type 2 diabetes, in the heart of the metabolic syndrome: plea for a global approach]. (2005) (1)
Another Prolactin-secreting Pituitary Tumor in an Insulindependent Diabetic Patient (1984) (1)
Body fat mass distribution. Influence on metabolic and atherosclerotic parameters in non-insulin dependent diabetics and obese subjects with and without impaired glucose tolerance. Influence of weight reduction. (1989) (1)
Insulin lispro (Humalog) in the treatment of diabetes mellitus: overview of belgian clinical data from global studies. (1999) (1)
Reverse T3 changes during protein supplemented diets. Relation to nutrient combustion rates. (1989) (1)
Endocrine abnormalities related to total and regional fat mass accumulation. (1992) (1)
A lesson from IVF endocrinology: the importance of the follicular phase to success and failure in non-IVF cycles. (1986) (1)
DNA sequencing and copy number variation analysis of MCHR2 in a cohort of Prader Willi like (PWL) patients. (2017) (1)
No important role for genetic variation in the Chibby gene in monogenic and complex obesity (2013) (1)
[Medication of the month. Rimonabant (Acomplia): first CB1 receptor antagonist of the endocannabinoid system]. (2008) (1)
An Intact Dopamine Sensitivity in the Brain: A Necessity to Recover Hyperprolactinemia and Galactorrhea in a Female Hemodialysis Patient? (2017) (1)
[Sitagliptin in the treatment of type 2 diabetes: insights five years after commercialisation]. (2013) (1)
Can calculated total nitrogen replace Kjeldahl total nitrogen measurements in 24-h urine samples? (2018) (0)
A targeted multi-omics approach reveals paraoxonase-1 as a determinant of obesity-associated fatty liver disease (2021) (0)
Influence of mebendazole administration on metabolic control in type 1 (insulin-dependent) diabetic patients. (1985) (0)
The "endocrine" dysmetabolism of visceral obesity. Lessons from exercise research. (1993) (0)
Pharmacologic Treatment of Obesity (2012) (0)
Insulinotropic effect of different formula of very low calorie protein supplemented diets in obesity. (1987) (0)
Myosteatosis is associated with early NASH in the context of obesity and metabolic syndrome (2020) (0)
Evolution of serum alpha-tocopherol in the postprandial and postabsorptive phases in type 1 diabetes mellitus. (2004) (0)
Glucagon and hyperkalaemia in decompensated diabetes. (1982) (0)
Upper body fat predominance: an endocrine and metabolic chaos. (1991) (0)
[CB1 receptor inhibition and glucose metabolism: role of rimonabant in type 2 diabetes]. (2008) (0)
[Course and treatment of diabetic nephropathy]. (1986) (0)
Efficacy and safety of high‐dose glucagon‐like peptide‐1, glucagon‐like peptide‐1/glucose‐dependent insulinotropic peptide, and glucagon‐like peptide‐1/glucagon receptor agonists in type 2 diabetes (2022) (0)
New pharmacological directions for the treatment of overweight and obesity. (1999) (0)
Insulin antibodies before and 1 year after the change-over from U40 to U100 insulin preparations in Belgium. (1994) (0)
Human obesity: a medical assessment of health risks. (1995) (0)
751-P: Effect Of Once-Weekly Semaglutide on Weight Change and Metabolic Control in People with Type 1 Diabetes—Six-Months Results from the Real-World STEMT Trial (2022) (0)
Body fat, body fat distribution and the respiratory system: a "fat neck" syndrome? (1992) (0)
[Value of the aminogram in the diabetic picture]. (1986) (0)
[In Process Citation] (2000) (0)
Nucleotide variation of sFRP5 gene is not associated with obesity in children and adolescents (2016) (0)
[Glycemic control before and after sitagliptin in general medical practice: analysis of determinant factors in the Belgian observational study "SUGAR"]. (2011) (0)
[Jentadueto, fixed combination of linagliptin plus metformin for the treatment of type 2 diabetes]. (2013) (0)
Long-term efficacy of semi-synthetic human insulins (SHI) in newly-diagnosed insulin-dependent diabetic patients. A two year clinical study. (1986) (0)
No important role for genetic variation in the Chibby gene in monogenic and complex obesity (2013) (0)
Metabolic syndrome--from controversies to ectopic fat syndrome. (2010) (0)
Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide 2.4 MG in Adults With Overweight or Obesity (STEP 1) (2021) (0)
[Transition from insulin U-40 to insulin U-100: the Belgian experience]. (1992) (0)
[Place of fibrates for the treatment of patients with atherogenic dyslipidemia]. (2009) (0)
[Risk factors for atherosclerosis in non-insulin-dependent diabetes]. (1992) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Luc F. Van Gaal?

Luc F. Van Gaal is affiliated with the following schools: